Campbell & Co Investment Adviser’s Royalty Pharma RPRX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.95M	Buy	52,688 +21,486	+69%	+$1.12M	0.15%	205
2026 Q1	$1.5M	Sell	31,202 -48,585	-61%	-$2.13M	0.09%	366
2025 Q4	$3.08M	Buy	+79,787	New	+$3.04M	0.15%	205
2025 Q2	–	Sell	-50,900	Closed	-$1.58M	–	1423
2025 Q1	$1.58M	Sell	50,900 -44,320	-47%	-$1.4M	0.12%	260
2024 Q4	$2.43M	Buy	95,220 +18,006	+23%	+$477K	0.19%	137
2024 Q3	$2.18M	Buy	77,214 +15,816	+26%	+$438K	0.16%	166
2024 Q2	$1.62M	Buy	61,398 +36,807	+150%	+$1.02M	0.14%	218
2024 Q1	$747K	Buy	24,591 +11,726	+91%	+$346K	0.06%	521
2023 Q4	$361K	Buy	+12,865	New	+$354K	0.03%	850
2023 Q3	–	Sell	-9,970	Closed	-$306K	–	1157
2023 Q2	$306K	Buy	+9,970	New	+$338K	0.05%	656

Other funds holding RPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking Tokyo, Japan $45.7B AUM 34.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Campbell & Co Investment Adviser's RPRX Position: Q2 2026 in Review

Campbell & Co Investment Adviser increased its Royalty Pharma (RPRX) stake by 69% in Q2 2026, buying an estimated $1.12M and bringing the position to 52,688 shares worth $2.95M. The position accounts for 0.15% of the portfolio, ranked #205.

Campbell & Co Investment Adviser first reported a position in RPRX in Q2 2023 and has held it in 10 quarters since. The position peaked at $3.08M in Q4 2025. 296 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Campbell & Co Investment Adviser held 52,688 shares of Royalty Pharma worth $2.95M as of Q2 2026.
Campbell & Co Investment Adviser bought 21,486 Royalty Pharma shares in Q2 2026, an estimated $1.12M.
Royalty Pharma made up 0.15% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #205 holding.
Campbell & Co Investment Adviser first reported a position in Royalty Pharma in Q2 2023 and has held it in 10 quarters since.
Campbell & Co Investment Adviser's Royalty Pharma position peaked at $3.08M in Q4 2025.
296 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.